These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
117 related articles for article (PubMed ID: 37884100)
1. Bicarbonate buffer dissolution test with gentle mechanistic stress for bioequivalence prediction of enteric-coated pellet formulations. Ikuta S; Nakagawa H; Kai T; Sugano K Eur J Pharm Sci; 2024 Jan; 192():106622. PubMed ID: 37884100 [TBL] [Abstract][Full Text] [Related]
2. Development of bicarbonate buffer flow-through cell dissolution test and its application in prediction of in vivo performance of colon targeting tablets. Ikuta S; Nakagawa H; Kai T; Sugano K Eur J Pharm Sci; 2023 Jan; 180():106326. PubMed ID: 36347443 [TBL] [Abstract][Full Text] [Related]
3. Dissolution Profiles of Oral Disintegrating Tablet with Taste Masking Granule Polymer Coating in Biorelevant Bicarbonate Buffer. Higashino M; Sugano K Chem Pharm Bull (Tokyo); 2024; 72(3):298-302. PubMed ID: 38479857 [TBL] [Abstract][Full Text] [Related]
4. Use of bicarbonate buffer systems for dissolution characterization of enteric-coated proton pump inhibitor tablets. Shibata H; Yoshida H; Izutsu K; Goda Y J Pharm Pharmacol; 2016 Apr; 68(4):467-74. PubMed ID: 27019275 [TBL] [Abstract][Full Text] [Related]
5. Regulating the pH of bicarbonate solutions without purging gases: Application to dissolution testing of enteric coated tablets, pellets and microparticles. Scott N; Patel K; Sithole T; Xenofontos K; Mohylyuk V; Liu F Int J Pharm; 2020 Jul; 585():119562. PubMed ID: 32565282 [TBL] [Abstract][Full Text] [Related]
6. In vitro stability, potency, and dissolution of duloxetine enteric-coated pellets after exposure to applesauce, apple juice, and chocolate pudding. Wells KA; Losin WG Clin Ther; 2008 Jul; 30(7):1300-8. PubMed ID: 18691989 [TBL] [Abstract][Full Text] [Related]
7. Accelerating the dissolution of enteric coatings in the upper small intestine: evolution of a novel pH 5.6 bicarbonate buffer system to assess drug release. Varum FJ; Merchant HA; Goyanes A; Assi P; Zboranová V; Basit AW Int J Pharm; 2014 Jul; 468(1-2):172-7. PubMed ID: 24727141 [TBL] [Abstract][Full Text] [Related]
8. Bioavailability of omeprazole 20 mg capsules containing omeprazole 22.5% enteric coated pellets versus a reference product in healthy Bangladeshi male subjects: an open-label, single-dose, randomized-sequence, two-way crossover study. Islam MS; Trini AB; Shohag H; Ahmed MU; Maruf AA; Hasnat A Int J Clin Pharmacol Ther; 2011 Dec; 49(12):778-86. PubMed ID: 22122821 [TBL] [Abstract][Full Text] [Related]
9. Physiologically relevant dissolution conditions towards improved in vitro - in vivo relationship - A case study with enteric coated pantoprazole tablets. Amaral Silva D; Gomes Davanço M; Davies NM; Krämer J; de Oliveira Carvalho P; Löbenberg R Int J Pharm; 2021 Aug; 605():120857. PubMed ID: 34229072 [TBL] [Abstract][Full Text] [Related]
10. Evolution of a physiological pH 6.8 bicarbonate buffer system: application to the dissolution testing of enteric coated products. Liu F; Merchant HA; Kulkarni RP; Alkademi M; Basit AW Eur J Pharm Biopharm; 2011 May; 78(1):151-7. PubMed ID: 21255647 [TBL] [Abstract][Full Text] [Related]
11. In vitro dissolution of proton-pump inhibitor products intended for paediatric and geriatric use in physiological bicarbonate buffer. Liu F; Shokrollahi H Int J Pharm; 2015 May; 485(1-2):152-9. PubMed ID: 25746736 [TBL] [Abstract][Full Text] [Related]
12. Bioequivalence of two enteric coated formulations of pantoprazole in healthy volunteers under fasting and fed conditions. de Campos DR; Vieira NR; Bernasconi G; Barros FA; Meurer EC; Marchioretto MA; Coelho EC; Calafatti SA; Sommer C; Couto JM; Buranello S; Silva AR; Amarante AR; Abib E; Júnior JP Arzneimittelforschung; 2007; 57(6):309-14. PubMed ID: 17688075 [TBL] [Abstract][Full Text] [Related]
13. Evaluation of the USP dissolution test method A for enteric-coated articles by planar laser-induced fluorescence. Miller DA; Gamba M; Sauer D; Purvis TP; Clemens NT; Williams RO Int J Pharm; 2007 Feb; 330(1-2):61-72. PubMed ID: 17034967 [TBL] [Abstract][Full Text] [Related]
14. Comparison of WHO and US FDA biowaiver dissolution test conditions using bioequivalent doxycycline hyclate drug products. Strauch S; Jantratid E; Dressman JB J Pharm Pharmacol; 2009 Mar; 61(3):331-7. PubMed ID: 19222905 [TBL] [Abstract][Full Text] [Related]
15. Comparative in vitro dissolution and in vivo bioequivalence of two diclofenac enteric coated formulations. Basmenji S; Valizadeh H; Zakeri-Milani P Arzneimittelforschung; 2011; 61(10):566-70. PubMed ID: 22164964 [TBL] [Abstract][Full Text] [Related]
16. Development and validation of dissolution tests for fexofenadine hydrochloride capsules and coated tablets. Breier AR; Paim CS; Steppe M; Schapoval EE J Pharm Pharm Sci; 2005 Aug; 8(2):289-98. PubMed ID: 16124939 [TBL] [Abstract][Full Text] [Related]
17. Lowly-buffered biorelevant dissolution testing is not necessarily biopredictive of human bioequivalence study outcome: Relationship between dissolution and pharmacokinetics. Matsui K; Nakamichi K; Nakatani M; Yoshida H; Yamashita S; Yokota S Int J Pharm; 2023 Jan; 631():122531. PubMed ID: 36563795 [TBL] [Abstract][Full Text] [Related]
18. A novel coating concept for ileo-colonic drug targeting: proof of concept in humans using scintigraphy. Varum FJ; Hatton GB; Freire AC; Basit AW Eur J Pharm Biopharm; 2013 Aug; 84(3):573-7. PubMed ID: 23348235 [TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetic properties and bioequivalence of 2 formulations of valsartan 160-mg tablets: A randomized, single-dose, 2-period crossover study in healthy Korean male volunteers. Kim JE; Ki MH; Yoon IS; Cho HJ; Kim RS; Tae Kim G; Kim DD Clin Ther; 2014 Feb; 36(2):273-9. PubMed ID: 24529292 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]